Skip to main content

131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System / Leptomeningeal Metastases

Trial Status: Active

Children with a neuroblastoma diagnose and central nervous system (CNS) / leptomeningeal metastases will be given up to 2 rounds of intracerebroventricular treatment with a radiolabelled monoclonal antibody, 131I-omburtamab to evaluate efficacy and safety

Inclusion Criteria

  • Patients must have a histologically confirmed diagnosis of neuroblastoma with relapse in the central nervous system or in the meninges (leptomeningeal).
  • Patients must be between the ages of birth and 18 years at the time of screening.
  • Patients must have a life expectancy of at least 3 months.

Exclusion Criteria

  • Patients with primary neuroblastoma in central nervous system.
  • Patients must not have an uncontrolled life-threatening infection.
  • Patients must not have received cranial or spinal irradiation less than 3 weeks prior to first dose of 131I-omburtamab in this trial.
  • Patients must not have received systemic chemotherapy (corticosteroids not included) less than 3 weeks prior to enrollment in this trial.
  • Patients must not have severe major non-hematologic organ toxicity; specifically, any renal, cardiac, hepatic, pulmonary, and gastrointestinal system toxicity must fall below Grade 3 prior to enrollment in this trial. Patients with stable neurological deficits (due to brain tumor) are not excluded. Patients with Grade 3 or lower hearing loss are not excluded.


Los Angeles
Children's Hospital Los Angeles
Status: ACTIVE


Riley Hospital for Children
Contact: Fernanda Rankin
Phone: 317-944-8784

New York

New York
Memorial Sloan Kettering Cancer Center
Contact: Kim Kramer
Phone: 212-639-6410


Nationwide Children's Hospital
Status: ACTIVE


M D Anderson Cancer Center
Status: ACTIVE

One 131I-omburtamab treatment cycle takes 4 weeks and includes a treatment dose, and an

observation period and post-treatment evaluations.

One 131I-omburtamab treatment cycle for Japan only takes 5 weeks and includes a dosimetry

dose (2mCi) of 131I-omburtamab is administered during week 1 followed by blood/cerebral

spinal fluid (CSF) samples and whole-body scintigraphy at predefined intervals during the

following 48 hours after treatment.

- A therapeutic dose (50mCi) of 131I-omburtamab is administered during week 1 (week 2 for

Japan) followed by a 3-week observation period that includes a repeated MRI, CSF

cytology, and safety monitoring.

- A second treatment cycle of 131I-omburtamab is administered during week 5 (week 6 for

Japan) if there is no objective disease progression week 5 after the first injection,

and the participant is presenting without unexpected and clinical significant Grade 4

toxicity. For participants with ongoing Grade 3 toxicity a second doing cycle will take

place according to the discretion of the investigator.

Participants can be treated in an outpatient setting or may be admitted as inpatients for

both the dosimetry and the therapeutic injections.

Participants completing at least one treatment period will first enter a follow-up period

through week 26 and thereafter the long-term follow-up where patients will be evaluated for

up to 3 years post-131I-omburtamab treatment where after the trial is ended

Participants will be monitored for adverse events during and after 131I-omburtamab injection

and will have pre- and post-treatment clinical assessments including neurologic examination,

hematology and serum chemistry, blood and CSF cultures, endocrinology assessments, CSF

analysis, and, pre- and post 131I-omburtamab performance testing. Performance testing will be

performed at trial baseline, at week 26 and every 6 months during trial period.

In case the patient has a subsequent relapse in the CNS/LM after 131I-omburtamab therapy

during the follow-up period, re-treatment to target minimal residual disease can be

considered and allowed.

Trial Phase Phase II/III

Trial Type Treatment

Lead Organization
Y-mAbs Therapeutics

  • Primary ID 101
  • Secondary IDs NCI-2019-00630
  • ID NCT03275402